2023 | Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. | JOURNAL OF CLINICAL ONCOLOGY |
2018 | Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
| PLOS ONE |
2018 | Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer | GYNECOLOGIC ONCOLOGY |
2017 | External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2022 | Feasibility and clinical applicability of genomic profiling based on cervical smear samples in patients with endometrial cancer
| FRONTIERS IN ONCOLOGY |
2023 | Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer | BRITISH JOURNAL OF CANCER |
2016 | Genetic analysis of ovarian microcystic stromal tumor
| Obstetrics & Gynecology Science |
2021 | Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix | MODERN PATHOLOGY |
2019 | Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer
| Cancer Research and Treatment |
2023 | Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer
| SCIENTIFIC REPORTS |
2020 | Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy | INTERNATIONAL JOURNAL OF CANCER |
2020 | Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
| BMC CANCER |
2023 | Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer
| SCIENTIFIC REPORTS |
2019 | How to use immune checkpoint inhibitor in ovarian cancer?
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2022 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2) RECEPTOR EXPRESSION AND ITS DYNAMIC CHANGE IN OVARIAN CANCER PATIENTS | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2023 | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | JAMA SURGERY |
2017 | Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls
| CANCER RESEARCH AND TREATMENT |
2022 | Identification of Lynch Syndrome in Patients with Endometrial Cancer Based on a Germline Next Generation Sequencing Multigene Panel Test
| CANCERS |
2015 | Identifying a low-risk group for parametrial involvement in microscopic Stage IB1 cervical cancer using criteria from ongoing studies and a new MRI criterion
| BMC CANCER |
2022 | IMMUNE PROPERTIES OF TUMOR-INFILTRATING LYMPHOCYTES IN OVARIAN CLEAR CELL CARCINOMA RELATIVE TO OVARIAN HIGH-GRADE SEROUS CARCINOMA | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2015 | Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer | EJSO |
2018 | Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2017 | Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
| PLOS ONE |
2023 | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
| PLOS ONE |
2021 | Impact of subcutaneous negative pressure drains on surgical wound healing in ovarian cancer | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2021 | Impact of the Learning Curve on the Survival of Abdominal or Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer
| CANCER RESEARCH AND TREATMENT |
2018 | Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. | GYNECOLOGIC ONCOLOGY |
2018 | In-bag power morcellation technique in single-port laparoscopic myomectomy
| Obstetrics & Gynecology Science |
2023 | Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019: Korea Central Cancer Registry
| Obstetrics & Gynecology Science |
2022 | Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study | GYNECOLOGIC ONCOLOGY |
2021 | Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee | GYNECOLOGIC ONCOLOGY |
2019 | Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2022 | Indocyanine green fluorescent image-guided inguinal sentinel lymph node biopsy in vulvar cancer
| Obstetrics & Gynecology Science |
2023 | Initial experience with the da Vinci SP robot-assisted surgical staging of endometrial cancer: a retrospective comparison with conventional laparotomy | JOURNAL OF ROBOTIC SURGERY |
2019 | Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer
| Yonsei Medical Journal |
2022 | Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
| FRONTIERS IN ONCOLOGY |
2023 | Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer | CLINICAL CANCER RESEARCH |
2016 | Knowledge of HPV and Surgery among Women Who Underwent Cervical Conization: A Korean Multi-Center Study
| YONSEI MEDICAL JOURNAL |
2022 | LAPAROSCOPIC LEFT COMMON ILIAC VEIN INJURY AND REPAIR | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2022 | LATE-BREAKING ABSTRACT PRESENTATION: COMPARATIVE EFFECTIVENESS OF HIPEC FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY: MULTICENTER, PROSPECTIVE, COHORT STUDY (KGOG 3042) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2017 | Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
| JOURNAL OF KOREAN MEDICAL SCIENCE |
2020 | Major clinical research advances in gynecologic cancer in 2019
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2022 | Major clinical research advances in gynecologic cancer in 2021
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2023 | Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2018 | MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
2023 | Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2021 | Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer | AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY |
2020 | Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
| BMC CANCER |
2022 | OREGOVOMAB AND NON-PLATINUM SINGLE AGENT CHEMOTHERAPY IN PARP INHIBITOR-RESISTANT OVARIAN CANCER PATIENTS NOT CANDIDATE FOR PLATINUM RETREATMENT: A MULTI-COHORT PHASE II STUDY (KGOG 3065/APGOT-OV6) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2019 | Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)
| BMC CANCER |
2018 | Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
| YONSEI MEDICAL JOURNAL |
2016 | Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease
| BMC CANCER |
2022 | PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
2019 | Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
| GYNECOLOGIC ONCOLOGY |
2022 | PATIENT-DERIVED ORGANOIDS AS A PRECLINICAL PLATFORM FOR PRECISION MEDICINE IN PATIENTS WITH CERVICAL CANCER | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
2019 | Patterns of initially overlooked recurrence of peritoneal lesions in patients with advanced ovarian cancer on postoperative multi-detector row CT | ACTA RADIOLOGICA |
2020 | Pelvic malakoplakia presenting as endometrial cancer: a case report
| Obstetrics & Gynecology Science |
2018 | Perioperative Outcomes of 3-Arm Versus 4-Arm Robotic Radical Hysterectomy in Patients with Cervical Cancer. | JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY |
2018 | Periumbilical infiltration of lidocaine with epinephrine for postoperative pain reduction in single-port laparoscopic adnexal surgery | JOURNAL OF OBSTETRICS AND GYNAECOLOGY |
2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |